HUA MEDICINE (SHANGHAI) LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.62 HKD | +1.89% |
|
+8.00% | -17.77% |
| Mar. 28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,688 | 4,214 | 4,628 | 2,956 | 3,194 | 1,468 | 1,468 | - |
| Enterprise Value (EV) 1 | 6,245 | 3,108 | 3,596 | 2,280 | 2,737 | 1,752 | 1,468 | 1,468 |
| P/E ratio | -2.13 x | -9.95 x | -11.9 x | -9.08 x | -15.7 x | -8.14 x | -6.31 x | 18.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 181 x | 22.9 x | 2.47 x | 1.36 x |
| EV / Revenue | - | - | - | - | 181 x | 22.9 x | 2.47 x | 1.36 x |
| EV / EBITDA | -18.9 x | -9.03 x | -12.9 x | -9.52 x | -13.6 x | -5.81 x | -5.98 x | -8.72 x |
| EV / FCF | -28,093,865 x | -12,002,195 x | -102,215,628 x | -10,081,667 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 1.86 x | 3.98 x | 6.32 x | 6.57 x | - | - | - | - |
| Nbr of stocks (in thousands) | 1,054,894 | 941,156 | 949,630 | 957,120 | 966,841 | 978,722 | 978,722 | - |
| Reference price 2 | 7.288 | 4.477 | 4.873 | 3.088 | 3.303 | 1.500 | 1.500 | 1.500 |
| Announcement Date | 3/7/19 | 3/16/20 | 3/19/21 | 3/16/22 | 3/29/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 17.6 | 76.61 | 594.3 | 1,079 |
| EBITDA 1 | -406.8 | -466.4 | -357.5 | -310.5 | -235.3 | -301.8 | -245.6 | -168.3 |
| EBIT 1 | -408.4 | -470.2 | -362.8 | -323.3 | -267.1 | -338.1 | -269.6 | -193 |
| Operating Margin | - | - | - | - | -1,517.8% | -441.28% | -45.37% | -17.89% |
| Earnings before Tax (EBT) 1 | -3,604 | -425.3 | -393.1 | -325.7 | -203.5 | -211.2 | -233.4 | 95.15 |
| Net income 1 | -3,603 | -425.3 | -393.1 | -325.7 | -203.5 | -211.2 | -233.4 | 80.87 |
| Net margin | - | - | - | - | -1,156.36% | -275.73% | -39.27% | 7.5% |
| EPS 2 | -3.425 | -0.4500 | -0.4100 | -0.3400 | -0.2100 | -0.2200 | -0.2375 | 0.0800 |
| Free Cash Flow | -273.7 | -351.1 | -45.27 | -293.2 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/7/19 | 3/16/20 | 3/19/21 | 3/16/22 | 3/29/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - | - | 17.6 | 70.33 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | -163.1 | -160.2 | -140.8 | -126.3 | -133.9 | - |
| Operating Margin | - | - | - | - | - | - | - | -717.63% | -190.37% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 1 | -0.2500 | -0.2000 | -0.1800 | -0.2300 | -0.1700 | -0.1700 | -0.1100 | -0.1000 | -0.0900 | 0.6300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/15/19 | 3/16/20 | 8/17/20 | 3/19/21 | 8/19/21 | 3/16/22 | 8/25/22 | 3/29/23 | 8/24/23 | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 1,443 | 1,106 | 1,032 | 675 | 457 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -274 | -351 | -45.3 | -293 | - | - | - | - |
| ROE (net income / shareholders' equity) | -124% | -34.5% | -43.8% | -55.1% | - | -27.8% | -6.49% | 11% |
| ROA (Net income/ Total Assets) | -32.2% | -31% | -32.1% | -31% | - | -17% | -4.05% | 7.58% |
| Assets 1 | 11,189 | 1,372 | 1,227 | 1,051 | - | -1,045 | 5,762 | 1,067 |
| Book Value Per Share | 3.920 | 1.130 | 0.7700 | 0.4700 | - | - | - | - |
| Cash Flow per Share | -0.7500 | -0.3600 | -0.0200 | -0.2900 | - | - | - | - |
| Capex 1 | 4.23 | - | 24.4 | 20.2 | - | 6.65 | 6.78 | 6.92 |
| Capex / Sales | - | - | - | - | - | 5.01% | 1.14% | 0.64% |
| Announcement Date | 3/7/19 | 3/16/20 | 3/19/21 | 3/16/22 | 3/29/23 | 3/28/24 | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.5
CNY
Average target price
3.072
CNY
Spread / Average Target
+104.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.77% | 203M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2552 Stock
- Financials Hua Medicine (Shanghai) Ltd.
